Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Ostrava – page 6

285 clinical trials in Ostrava, Czechia across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Ostrava at a glance
285
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

285 trials in Ostrava

Open in trial search

Immune thrombocytopenia

Recruiting

Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Acute lymphocytic leukaemia+1

Recruiting

Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Ascentage Pharma Group Inc.

Diabetic retinal oedema

Recruiting

Study of oral BI 1815368 compared to placebo in patients with diabetic macular edema over 48 weeks of treatment

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Boehringer Ingelheim International GmbH

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Alnylam Pharmaceuticals Inc.

Plasma cell myeloma

Recruiting

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Secondary immunodeficiency

Recruiting

Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Takeda Development Center Americas Inc.

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Neovascular age-related macular degeneration+1

Recruiting

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Triple negative breast cancer

Recruiting

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Endometrial cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Primary biliary cholangitis

Recruiting

Study of Seladelpar Treatment in Patients with Primary Biliary Cholangitis and Compensated Cirrhosis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Seladelpar
  • Sponsor:Gilead Sciences Inc.

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Ostrava

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic prostate cancer and lung cancer treatments. Studies include evaluation of novel therapies for multiple myeloma and various forms of leukemia.

  • Prostate Cancer Treatment Advances
  • Small Cell Lung Cancer Therapy
  • Blood Cancer Interventions

Multiple collaborative studies exploring targeted therapies and combination treatments for advanced-stage cancers.

02 Immunology and Inflammatory Diseases

Research targeting inflammatory bowel diseases, including studies on Crohn's Disease and ulcerative colitis. Investigations into novel treatments for psoriatic arthritis.

  • Inflammatory Bowel Disease Management
  • Autoimmune Conditions
  • Chronic Inflammatory Disorders

Comprehensive evaluation of innovative therapeutic approaches for chronic inflammatory conditions.

03 Cardiovascular and Infectious Diseases

Studies examining cardiovascular disease treatments and prevention strategies. Research on bacterial infections and antimicrobial therapies, including trials for complicated urinary tract infections.

  • Heart Disease Prevention
  • Infection Management
  • Antibiotic Optimization

Advanced research combining preventive approaches with targeted therapeutic interventions.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.